清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

溃疡性结肠炎 医学 内科学 选择(遗传算法) 结肠炎 胃肠病学 计算机科学 人工智能 疾病
作者
Edward V Loftus,Séverine Vermeire,Brian G Feagan,Franck-Olivier Le Brun,Alessandra Oortwijn,Ulrik Moerch,William J Sandborn,Toshifumi Hibi
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
标识
DOI:10.1093/ecco-jcc/jjac122
摘要

Abstract Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC. Methods These post hoc analyses assessed 1-, 3-, 6-, and 8-month rates of corticosteroid-free clinical remission at Week 58 and change in median daily prednisone-equivalent dose over time. A matching-adjusted indirect comparison [MAIC] of maintenance studies assessed corticosteroid-free remission with filgotinib 200 mg, intravenous vedolizumab, subcutaneous vedolizumab, and oral tofacitinib. Results The Maintenance Study full analysis set included 199 patients receiving filgotinib 200 mg and 98 receiving placebo. Among patients receiving corticosteroids at Maintenance Study baseline, at Week 58, 30.4%, 29.3%, 27.2%, and 21.7% receiving filgotinib had been in corticosteroid-free remission for ≥1, ≥3, ≥6, or ≥8 months, respectively, versus 6.4% receiving placebo across thresholds [p <0.05]. Median daily prednisone-equivalent dose decreased from 17.5 mg/day to 10.0 mg/day with filgotinib treatment during the Maintenance Study. Based upon the MAIC, filgotinib was associated with greater likelihood of corticosteroid-free clinical remission versus intravenous vedolizumab (odds ratio [OR], 15.2; 95% confidence interval [CI], 1.6–139.9; p <0.05]) and similar odds to subcutaneous vedolizumab [OR, 3.8; CI, 0.2–63.8; p = 0.36] in biologic-naïve patients, and similar odds to tofacitinib overall [OR, 2.0; 0.4–9.1; p = 0.39]. Conclusions Filgotinib 200 mg demonstrated corticosteroid-sparing effects and maintained corticosteroid-free clinical remission in patients with UC. MAIC results should be interpreted cautiously given the large CIs and differences in study design and patient populations. [ClinicalTrials.gov: NCT02914522].

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
12秒前
future完成签到 ,获得积分10
15秒前
22秒前
量子星尘发布了新的文献求助10
23秒前
31秒前
31秒前
红毛兔完成签到 ,获得积分10
32秒前
不能吃太饱完成签到 ,获得积分10
38秒前
44秒前
49秒前
顾矜应助Dmyb采纳,获得10
53秒前
1分钟前
猪仔5号完成签到 ,获得积分10
1分钟前
1分钟前
尔玉完成签到 ,获得积分10
1分钟前
1分钟前
45度人发布了新的文献求助10
1分钟前
bkagyin应助45度人采纳,获得10
1分钟前
分析完成签到 ,获得积分10
1分钟前
45度人完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
打打应助ycyang采纳,获得30
1分钟前
fangting发布了新的文献求助10
1分钟前
2分钟前
yhbk完成签到 ,获得积分10
2分钟前
mr完成签到 ,获得积分10
2分钟前
科科通通完成签到,获得积分10
2分钟前
咯咯咯完成签到 ,获得积分10
2分钟前
yiqi完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
Dmyb发布了新的文献求助10
2分钟前
陳某发布了新的文献求助10
2分钟前
午后狂睡完成签到 ,获得积分10
2分钟前
SUT文献战神完成签到,获得积分10
2分钟前
雨的痕迹发布了新的文献求助10
2分钟前
lod完成签到,获得积分10
2分钟前
3分钟前
陶醉沅完成签到,获得积分10
3分钟前
量子星尘发布了新的文献求助10
3分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976713
求助须知:如何正确求助?哪些是违规求助? 3520805
关于积分的说明 11204821
捐赠科研通 3257587
什么是DOI,文献DOI怎么找? 1798771
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806648